High-density lipoproteins (HDLs) protect against atherosclerosis mainly due to their function in hepatobiliary reverse cholesterol transport (RCT). This is a process whereby excess cholesterol from peripheral tissues is transported by HDL particles to the liver for further metabolism and biliary excretion. Hepatic uptake of HDL holoparticles involves the P2Y 13 receptor, independently of the selective cholesteryl ester uptake mediated by scavenger receptor class B, type I (SR-BI). Accordingly, P2Y 13 -deficient mice (P2Y 13 2/2 ) have impaired RCT. This study assessed whether P2Y 13 deficiency would affect atherosclerotic development.
Introduction
Several large prospective studies have established that high-density lipoprotein (HDL) cholesterol is an independent negative risk factor for coronary artery disease and a major protective factor against atherosclerosis. 1 The atheroprotective effects of HDL particles have been attributed to several mechanisms, which primarily reflect their ability to promote reverse cholesterol transport (RCT), a major pathway for removing excess cholesterol from the body. The classic RCT pathway is a multistep process which involves (i) HDL-mediated efflux of excess cholesterol from extrahepatic cells, and particularly from atherosclerosis lipid laden macrophages in the arterial wall, (ii) HDL uptake by hepatocytes, and (iii) excretion of cholesterol from HDL into the bile and ultimately faeces, either directly or after metabolic conversion into bile acids (BAs).
Two pathways for HDL uptake by hepatocytes have been identified. The first involves the scavenger receptor class B, type I (SR-BI) that mediates selective uptake of cholesteryl ester (CE) from HDL by the liver. 2, 3 The second involves an ecto-F 1 -ATPase expressed at the plasma membrane of hepatocytes and contributes to the uptake of both protein and lipid moieties of the HDL particle, a process called HDL holoparticle endocytosis. 4 More precisely, apolipoprotein A-I (apoA-I, the major protein component of HDL) binds to the ecto-F 1 -ATPase and stimulates the hydrolysis of extracellular ATP to ADP. The extracellular ADP generated then selectively activates the P2Y 13 purinergic receptor, resulting in cytoskeleton reorganization and subsequent clathrin-dependent endocytosis of HDL holoparticles through a low-affinity receptor that has yet to be identified. 5 -7 In addition to the hepatocytes, P2Y 13 receptor mRNA is also expressed in neurons, osteoblasts, and immune cells such as monocytes, T cells, and dendritic cells. 8 However, it does not seem to be involved in the immune response, at least not in immunological dendritic cell functions. 9, 10 Consistent with the role of P2Y 13 in HDL uptake by hepatocytes, hepatic HDL uptake, associated with reduced biliary sterol secretions and impaired macrophages-to-faeces RCT, was much lower in homozygous null P2Y 13 -knockout (KO) mice (C57BL/6 P2Y 13 2/2 ) faeces than in C57BL/6 wild-type (WT) littermates. 11, 12 Thus, because macrophages-to-faeces RCT is strongly associated with atherosclerosis, we wished to explore the potential involvement of P2Y 13 receptor in the development of atherosclerosis. We recently observed that despite dramatically impaired RCT, P2Y 13 2/2 mice fed a high cholesterol diet (1.25% cholesterol) have just as little lipid deposition in the aortic sinus as their WT littermates. 13 However, this was not completely unexpected because lipoprotein metabolism in mice is different from that in humans, and WT mice have low levels of atherogenic apoB-lipoproteins, a limiting factor for cholesterol-induced atherogenesis. 14 In this context, the apolipoprotein E-deficient (apoE 2/2 ) mouse model has the advantage that it spontaneously develops atherosclerotic lesions. These lesions have many of the characteristics of those in humans with high levels of atherogenic apoB-lipoproteins and limited immune-mediated inflammatory responses at the early stage. 15 We therefore crossed apoE 2/2 with P2Y 13 2/2 mice to generate P2Y 13 /apoE double-KO mice (P2Y 13 2/2 /apoE 2/2 ). These animals were maintained on regular chow before collection of their hearts for analysis of the size and composition of atherosclerotic lesions. These lesions were bigger and more infiltrated with macrophages in P2Y 13 2/2 / apoE 2/2 compared with apoE 2/2 mice. Bone marrow (BM) transplantation was performed to determine the relative contribution to the development of atherosclerosis of the P2Y 13 receptors expressed on blood cells and in the rest of the body. The results exclude the involvement of blood cell P2Y 13 receptors and confirm a role of the P2Y 13 receptors in the liver since, compared with apoE 2/2 mice, P2Y 13 2/2 / apoE 2/2 mice displayed profoundly impaired hepatobiliary secretion of sterols associated with reduced excretion of sterols in the faeces and reduced macrophages-to-faeces RCT.
Methods

Materials
All reagents (analytical grade) were from Sigma. Horseradish peroxidase (HRP)-conjugated anti-rabbit antibodies were purchased from Cell Signaling Technology (distributed by Ozyme, Saint-Quentin en Yvelines, France). The enhanced chemiluminescence system was purchased from Amersham Biosciences, Inc. (Orsay, France). 3H-cholesterol was purchased from PerkinElmer (Courtaboeuf, France).
Animals and diets
All animals used were male mice on the C57BL/6 genetic background. P2Y 13 / apoE double-KO mice (P2Y 13 2/2 /apoE 2/2 ) were generated by crossing P2Y 13 2/211 with apoE 2/2 mice (Jackson Laboratory, Bar Harbor, ME, USA).
Littermate controls were from the breeding colony. Mice were caged in animal rooms with L : D 12 : 12 and ad libitum access to water and chow diet (# R04-10, SAFE, France) for 15 weeks. Heart tissue was taken from 15-week-old mice. All other procedures were carried out on 15-week-old mice unless otherwise stated. During experiments, mice were anaesthetized using isoflurane (2%) and were euthanized using cervical dislocation. All animal procedures were performed in accordance with the guidelines of the Committee on Animals of the Midi-Pyrénées Ethics Committee on Animal Experimentation and with the French Ministry of Agriculture license. Moreover, this investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health or the Directive 2010/63/EU of the European Parliament.
Atherosclerotic lesion characterization in the aortic sinus
ApoE
2/2 and P2Y 13 2/2 /apoE 2/2 mice were killed, and their heart and ascending aorta removed. These tissues were washed in PBS and kept at 48C for 24 h. Each heart was frozen on a cryostat mount with optimum cutting temperature compound (Tissue-Tek), and stored at 2808C. Aortic sinus sections were processed according to our standard method. 13 For immunostaining, frozen sections from the aortic root were fixed in acetone/methanol, air-dried, and incubated with 10% relevant serum for 30 min. The specific primary antibody used was anti-monocyte/ macrophage (clone MOMA-2, Serotec, Oxford, UK). The sections were then incubated with the corresponding secondary biotinylated antibodies (Dako) and visualized with an avidin -biotin -HRP complex (Vectastain ABC Kit, Vector Laboratories) and the 3,3 ′ diaminobenzidine peroxidase substrate kit (DakoCytomation, Glostrup, Denmark). Countercolouration was performed with Mayer's haematoxylin. Irrelevant IgGs were used as a negative control. At least five sections per mouse were examined for each staining.
BM transplantation
To induce BM aplasia, apoE 2/2 (apoE KO) and P2Y 13 2/2 /apoE 2/2 (double KO, dKO) 7-week-old male mice were exposed to a single dose of 9 Gy (2.8 Gy/min) total body irradiation using a BIOBEAM gamma irradiation device (Gamma-Service Medical GmbH) 1 day before the transplantation. We isolated BM cells from donor apoE KO and dKO mice, by flushing their femurs and tibias with sterile PBS. Single-cell suspensions were prepared by passing the cells through a 30 mm nylon gauze. 16 Mice were euthanized and their hearts collected and processed as described in Section 2.3. Successful engraftment was confirmed by PCR.
Plasma lipoprotein analyses
Individual plasma samples were collected from apoE 2/2 and P2Y 13 2/2 / apoE 2/2 mice that had received no food for 3 h. Total cholesterol and triglycerides (TGs) were measured with commercial kits (CHOD-PAP for cholesterol and GPO-PAP for TGs; BIOLABO SA, Maizy, France). Quantification of plasma lipoproteins was performed using an Ultimate w 3000 HPLC system (Dionex, USA). About 10 mL of plasma was injected and lipoproteins were separated on Superose w 6 10/300GL columns (GE Healthcare, USA) with PBS at pH 7.4 as mobile phase at a 0.5 mL/min flow rate. The column effluent was split equally into two lines by a microsplitter 50 : 50, mixing with cholesterol and/or TG reagents (BIOLABO), thus achieving a simultaneous profile from single injection. The two enzymatic reagents were each P2Y 13 receptor in atherosclerosis pumped at a rate of 0.1 mL/min using ISO-3100 analytical pumps (Dionex). Both enzymatic reactions proceeded at 408C in a reactor coil (10 m × 0.5 mm, i.d.). Quantification was performed by measuring the percentage peak area of each lipoprotein (VLDL, LDL, and HDL) and by multiplying each percentage to the total amount of cholesterol and/or TGs measured in plasma samples.
Hepatic lipid analyses
Hepatic cholesterol and TGs were analysed, following Bligh and Dyer lipid extraction, by gas -liquid chromatography following standard methods. 11 
Biliary and faecal lipid analysis
ApoE
2/2 and P2Y 13 2/2 /apoE 2/2 mice were starved for 3 h and were then anaesthetized by intraperitoneal injection of ketamine hydrochloride (100 mg/kg) and xylazine hydrochloride (15 mg/kg). At 11.00 a.m., the gallbladder was cannulized and bile was collected for 30 min, after a stabilization time of 30 min. Bile flow was determined gravimetrically and output rates of BAs, cholesterol, and phospholipids were calculated by multiplying bile flow and concentration following our standard method. 17 Faeces were collected for 48 h, lyophilized, and ground. Faecal neutral sterols and BA content were analysed after homogenization of 100 mg of faeces in 1 mL of purified water. For neutral sterols, the homogenates were analysed by gas-liquid chromatography, following Bligh and Dyer lipid extraction. For BAs, the faecal homogenates were acidified with 1 M acetic acid in 750 mL of methanol, then the mixture was centrifuged at 3500 × g for 10 min. The supernatant was then extracted by solid-phase extraction and finally eluted with methanol/water (90/10, v/v). The solution obtained was evaporated under vacuum and suspended in 100 mL of methanol. After centrifugation at 20 000 × g for 2 min, 25 mL of the supernatant was injected into the HPLC C18 column for analysis.
Analysis of hepatic gene expression by real-time quantitative PCR
Liver RNA isolation, reverse transcription, and real-time quantitative PCR analysis were performed by standard methods. 17 The level of mRNA expression in apoE 2/2 / P2Y 13 2/2 mice was calculated relative to the average of the housekeeping gene RPS29 and further normalized to the relative expression level in apoE 2/2 mice (eight mice per group).
Western blot
Individual mouse livers were homogenized using the Precellys w lysing kit in TNE buffer [Tris-HCl (50 mM), NaCl (100 mM), and EDTA (0.1 mM) 1% NP40] containing a protease inhibitor cocktail (leupeptin, aprotinin, and pepstain A). Protein concentration was measured using the Bradford method (Biorad). Tissue homogenates (100 mg) were subjected to SDS-PAGE electrophoresis under reducing conditions, transferred onto PVDF membranes (Millipore), and analysed by immunoblotting according to standard protocols using the antibodies indicated. We used a rabbit mAb against mouse SR-BI (clone EP1556Y) from Abcam and a mouse mAb against b-actin (clone AC-15) from Sigma. HRP-labelled secondary antibodies were from Sigma. Quantification was carried out using the Image J software.
In vivo macrophage-to-faeces RCT
The RCT assay was performed by standard methods. 13 Briefly, thioglycollate-elicited mouse peritoneal macrophages, harvested from apoE 2/2 donor mice, were loaded for 24 h with 50 mg/mL of acetylated LDL and 5 mCi/mL of 3 [H]-cholesterol, then injected intraperitoneally in recipient mice (2 million dpm/mouse). Blood samples were taken 6, 24 and 48 h after macrophage injection, faeces were collected continuously for 48 h, and livers were harvested 48 h after macrophage injection and stored at 2808C until lipid extraction and radioactivity counting. 13 All counts were expressed as a percentage of the administered tracer dose.
HDL functionality assays
HDL were isolated mouse plasma after precipitation of apoB-containing lipoproteins with polyethylene glycol-6000. 18 The antioxidative property of HDL was assessed by measuring the capacity of HDL to inhibit the oxidation of native LDL. 18, 19 The anti-inflammatory property of HDL was evaluated on human umbilical vein endothelial cells (HUVECs) by measuring MCP-1 gene expression by standard methods. 18 The efflux experiments were performed by measuring cholesterol efflux for 5 h from primary mouse peritoneal macrophages towards either plasma (1%, v/v) or apoBdepleted lipoproteins (2%, v/v) using standard methods. 18 2.12 Cholesterol efflux towards HDL and apoA-I
HDLs were isolated from the plasma of normolipidaemic healthy human donors by standard sequential ultracentrifugation of discontinuous KBr gradients. 20 ApoA-I was isolated from HDL by ion-exchange chromatography following our established protocol. 21 The cholesterol efflux assay was carried out on thioglycollate-elicited mouse peritoneal macrophages of apoE 2/2 and P2Y 13 2/2 /apoE 2/2 mice.
Cells were labelled for 24 h with 50 mg/mL of acetylated LDL and 5 mCi/mL of 3 [H]-cholesterol. The next day, the cells were washed with fresh media. They were then incubated with fresh DMEM (1 mg/mL of fatty acid free BSA) with free human apoA-I (10 mg/mL), or human HDL (100 mg/mL) at 378C for 3 h. The medium was removed and clarified of cellular material, then cholesterol efflux was quantified by scintillation counting. The cell layers were lysed in 0.1 N NaOH, and cellular cholesterol content quantified by scintillation counting. Cholesterol efflux was expressed as the percentage effluxed [media counts/(media counts + cellular counts) × 100].
Statistical analysis
All results are presented as means + SEM. Comparison between groups was made using the Mann-Whitney test for independent samples. Differences between more than two groups were analysed by two-way analysis of variance (ANOVA) followed by Bonferroni's post hoc test if necessary. Outcomes of P , 0.05 were considered statistically significant. Analyses were performed using the GraphPad Prism 6 software.
Results
3.1 P2Y 13 receptor protects against atherosclerosis development on the apoE 2/2 background We further investigated the effect of P2Y 13 receptor deficiency in apoE 2/2 mice on atherosclerotic development at 15 weeks of age.
We observed more lipid-rich atherosclerotic plaque deposition and macrophage content in the aortic arch of P2Y 13 2/2 /apoE 2/2 , than in apoE 2/2 , mice ( Figure 1A and B Figure 1C ). This is consistent with the greater atherosclerosis Figure 1 Atherosclerotic plaque characterization, and immune cell contribution in atherosclerotic development. (A) Cross-sectional aortic root lesion quantification from apoE 2/2 (n ¼ 9) and P2Y 13 2/2 /apoE 2/2 (n ¼ 8) mice. Representative image of Oil Red O-stained aortic roots from apoE 2/2 and P2Y 13 2/2 /apoE 2/2 mice (original magnification ×50). (B) Adjacent sections of aortic roots with atherosclerotic lesion were stained with anti-monocytes/macrophages (clone MOMA-2) and quantified (apoE 2/2 , n ¼ 7; P2Y 13 2/2 /apoE 2/2 , n ¼ 9). Representative image of MOMA-2-stained aortic root sections (original magnification ×400). (C) apoE 2/2 (KO) and P2Y 13 2/2 /apoE 2/2 (dKO) mice were irradiated and reconstituted with BM as described in Section 2 (KO . KO, n ¼ 6; dKO . KO, n ¼ 7; dKO . dKO, n ¼ 6; and KO . dKO, n ¼ 6). Representative image of Oil Red O-stained aortic root sections (original magnification ×50). Each dot represents the mean plaque area + SEM in the aortic root from five sections of the sinus from each mouse. Statistical significance was determined by using the Mann-Whitney test for independent samples (A and B) and the two-way ANOVA followed by Bonferroni post-test (C). *P , 0.05, ***P , 0.001 compared with indicated values. Table 2) .
Interestingly, this impaired secretion of lipid into the bile resulted in lower cholesterol and BA excretion from the body, as indicated by the lower cholesterol and BA content in the faeces of P2Y 13 2/2 /apoE 2/2 compared with those of apoE 2/2 mice ( of other HDL/apoA-I receptors involved in HDL uptake and biogenesis by the liver, namely SR-BI, ATP-binding cassette transporter A1 (ABCA1), and ABCGI. There was much higher mRNA expression for SR-BI in the liver of P2Y 13 2/2 /apoE 2/2 than in those of apoE 2/2 mice (2.67 + 0.29-fold, P , 0.01), whereas mRNA levels of ABCA1 and ABCG1 were unchanged between the two genotypes ( Figure 4A ). The increase in SR-BI gene expression translated into up-regulation of SR-BI protein expression in the liver of P2Y 13 2/2 /apoE 2/2 than in apoE 2/2 mice (4.14 + 1.19-fold, P , 0.05, Figure 4B ). This suggests that the mice adjust hepatic SR-BI expression to compensate for the loss of functioning P2Y 13 receptors and the associated lack of HDL holoparticle endocytosis. and apoE 2/2 mice ( Figure 5A and B) . However, the radioactivity found in faeces was significantly lower in P2Y 13 2/2 /apoE 2/2 than in apoE
mice, both for radioactivity associated with BAs and for that associated with neutral sterols (266.11 + 3.17 and 247.17 + 6.46%, respectively, Figure 5C ). This reflects the association of P2Y 13 receptor deficiency in apoE 2/2 mice with impaired RCT in vivo, as already known for P2Y 13 2/2 mice compared with WT P2Y 13 +/+ mice. 3.6 Unchanged functional properties of HDL particles from P2Y 13 2/2 /apoE 2/2 mice
We analysed whether P2Y 13 deficiency in apoE 2/2 mice modified the functionality of HDL particles. We observed that isolated HDL particles from P2Y 13 2/2 /apoE 2/2 mice did not differ in either their antiinflammatory or antioxidative properties from those in HDL from apoE 2/2 mice ( Figure 6A and B) . Plasma from P2Y 13 2/2 /apoE 2/2 and apoE 2/2 mice displayed similar cholesterol efflux capacity, measured from 3 [H]-cholesterol-loaded bone marrow-derived macrophages ( Figure 6C) . Accordingly, there were identical effluxes to HDL particles isolated from a fixed amount of plasma for both P2Y 13 2/2 /apoE 2/2 and apoE 2/2 mice ( Figure 6D ). Since plasma HDL-C was lower in P2Y 13 2/2 / apoE 2/2 than in apoE 2/2 mice, we also determined cholesterol efflux towards HDL after correcting for the cholesterol mass level present in the sample. This measure was also similar in P2Y 13 2/2 /apoE 2/2 and apoE 2/2 mice ( Figure 6E ), indicating that P2Y 13 deficiency does not modify cholesterol efflux capacity of HDL per se. In addition, we also observed similar cholesterol efflux to purified human apoA-I or HDL from macrophages of P2Y 13 2/2 /apoE 2/2 and apoE 2/2 mice (see Supplementary material online, Figure S1 ), indicating that P2Y 13 deficiency in macrophages does not influence cholesterol efflux capacity.
Discussion
We report here that the P2Y 13 receptor plays a protective role in the development of early atherosclerotic lesions. At 15 weeks of age, the lesions formed in the aortic root of P2Y 13 2/2 /apoE 2/2 mice were larger than those in apoE 2/2 mice. Macrophages content was also greater compared with apoE 2/2 animals. In addition to expression in hepatocytes, P2Y 13 receptor mRNA is expressed in some haematopoietic mice. Faeces were collected over 48 h. BA and neutral sterol contents of the faeces were determined as described in Section 2. Data are given as mean + SEM; n ¼ 8 mice per group. Statistical significance was determined by using the Mann-Whitney test for independent samples. *P , 0.05 compared with apoE secretion of all biliary lipids, associated with lower output of both neutral sterols and BAs in the faeces. Therefore, tracer recovery in faecal neutral sterols and BAs was also lower when RCT from macrophages to faeces is measured. It is interesting that these changes differ from the phenotype of SR-BI-deficient mice in which only biliary secretion of cholesterol is low, not that of other lipids. 25 This difference indicates that the P2Y 13 -mediated HDL endocytosis pathway is essential for driving the overall flux of lipids through the liver into the bile for ultimate secretion into faeces.
This metabolic phenotype of P2Y 13 2/2 /apoE 2/2 mice is partially consistent with low HDL endocytosis into the liver in P2Y 13 KO mice. 11 This was also associated with impaired hepatobiliary RCT. 6, 11, 12 However, dKO mice display an unexpected low level of HDL-C (233 + 6%, P , 0.05) and to a lesser extent of LDL-C (213 + 4%, P , 0.05) ( Table 1) . However, given the role of P2Y 13 receptors in HDL endocytosis by hepatocytes, inactivation of this receptor would be expected to produce high rather than low HDL-C levels. One explanation of this discrepancy is that P2Y 13 receptor deficiency in apoE 2/2 mice leads to compensatory changes in the hepatic expression of SR-BI. And, indeed, protein expression was up-regulated in the liver of P2Y 13 2/2 /apoE 2/2 mice. These observations are concordant with the fact that mice with liver-specific overexpression of SR-BI transgene (SR-BI-Tg Liver ) display low HDL-C plasma level and high hepatic cholesterol content. 26, 27 In addition, due to the ability of SR-BI to bind LDL and VLDL and to promote the clearance of these lipoproteins, 28 -32 SR-BI-Tg Liver mice display low plasma levels of LDL-C, VLDL-C, and TG. 27 These changes resemble these occurring in P2Y 13 2/2 /apoE 2/2 mice, which suggests that the low levels of LDL-C and VLDL-TG in these mice could also be related to high expression of SR-BI in the liver. The regulatory mechanisms responsible for the up-regulation of SR-BI in P2Y 13 2/2 / apoE 2/2 mice will require further investigation, although it is more likely to be transcriptional rather than post-transcriptional given that both mRNA and protein expression levels of SR-BI were high but that mRNA expression levels of PDZK1, a post-transcriptional regulator of SR-BI, 33 were unchanged (not shown).
It is of interest that mice overexpressing SR-BI in the liver have high biliary cholesterol secretion and macrophage-RCT, which translates into a low incidence of atherosclerosis. 34 -36 However, we observed here that P2Y 13 2/2 /apoE 2/2 mice display a totally reversed phenotype.
Thus, the up-regulation of SR-BI in P2Y 13 2/2 /apoE 2/2 mice, besides reducing the HDL-C level, fails to compensate in vivo for the adverse effects of P2Y 13 receptor deficiency on RCT and atherosclerosis. Furthermore, it is possible that SR-BI activity in P2Y 13 2/2 /apoE 2/2 mice is less up-regulated than is the expression of the corresponding protein since apoE 2/2 mice display low SR-BI activity in promoting selective uptake of CE from HDL. 37 This is in line with data from animal models for other RCT targets: the association between HDL-C levels and macrophage-specific RCT is thus not straightforward, indicating that HDL-C levels should be used with caution as a surrogate for predicting fluxes through the RCT pathway. 38 Overall, our data argue for a central role for the P2Y 13 receptor, which in our model cannot be substituted for by SR-BI, in the process of bile lipid secretion and of RCT and document an anti-atherogenic function of the P2Y 13 receptor.
Our results also confirm the interesting strict relationship of P2Y 13 receptor activity to the function of HDL in hepatobiliary RCT. The strictness of this relationship is clear because no other HDL properties, such as anti-inflammatory or antioxidative properties, nor the HDL capacity to elicit efflux from cholesterol-loaded macrophages, differed between HDL from P2Y 13 2/2 /apoE 2/2 and that from apoE 2/2 mice. Likewise, these properties do not differ between HDL from P2Y 13 2/2 and that from WT P2Y 13 +/+ mice, 13 suggesting that P2Y 13 receptor does not contribute to the protective effect of HDL on immunoinflammatory responses. Recently, the effects of P2Y 13 receptor activation in mice were investigated in two independent studies using two P2Y 13 receptor agonists, namely Cangrelor (The Medicine Company, NJ, USA) and CT1007900 (Cerenis Therapeutics, Toulouse, France). In WT (C57/Bl6) mice, these compounds stimulate plasma HDL clearance and HDL endocytosis by the liver so increasing biliary lipid secretion and stimulating overall RCT. 11, 17, 22 Regarding the agonist specificity, none of these metabolic changes have been reported in P2Y 13 2/2 mice or mice treated with adenovirus P2Y 13 -shRNA. 11, 22 Note that CT1007900 stimulates RCT in apoE 2/2 mice, as it does in WT mice, and reduces atherosclerosis after 1 month of treatment. 22 Thus, basically, data from P2Y 13 receptor activation as well as the loss-of-function studies reported here result in complementary phenotypes, including metabolic parameters and atherosclerotic development.
In conclusion, our study demonstrates in vivo that the P2Y 13 receptor is a key component of the hepatobiliary RCT process and clearly indicates that P2Y 13 receptor protects against the development of atherosclerosis, at least in mice. In the context of recent failures of clinical trials of agents developed to raise HDL-C levels, failures that have introduced considerable controversy to this field, 39, 40 our study supports the concept that future HDL therapies need to target HDL functions, for instance by improving HDL particle flux to the liver, rather than simply increasing HDL-C. Thus, involvement of the P2Y 13 receptor in HDL-mediated RCT makes it an attractive target for therapeutic intervention against atherosclerotic lesion development.
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